grow any bacterial species. One month following the procedure, the patient became non-weight-bearing lame on the right forelimb, and the wound became ulcerated. The cat was recommenced on marbofloxacin (5 mg/kg PO q24h), cefovecin (8 mg/kg SC) and meloxicam (0.3 mg/kg SC). The biopsied tissue was then submitted for histopathology, approximately 2 months after it had been collected. Histological examination of the biopsy revealed medium-to-large-sized neoplastic round cells infiltrating through the dermis and subcutis, most consistent with a cutaneous roundcell tumour. There was no evidence of epitheliotropism ( Figure 2 ). The neoplastic cells showed high mitotic Two weeks later, the cat presented to Victorian Animal Cancer Care, Melbourne, Australia, where the primary lesion was ulcerated and swollen ( Figure 4) . On clinical examination, the right pre-scapular and right axillary lymph nodes were enlarged, measuring 2.3 × 2.2 × 2.0 cm and 1.5 × 2.0 × 2.0 cm, respectively. All other peripheral nodes were within normal limits. Fine-needle aspiration and cytology from the right pre-scapular and axillary lymph nodes revealed large atypical lymphocytes with round, irregularly lobulated nuclei, varied nuclear size and high levels of mitotic figures, consistent with a large-cell, likely high-grade lymphoma. Haematology and serum biochemical analyses were performed. Cytological examination of peripheral blood revealed rare atypical lymphocytes; however, the haematology panel was otherwise unremarkable. There was a mild elevation in aspartate transaminase (122 U/l; reference interval [RI] 10-60 U/l) and creatine kinase (439 U/l; RI 50-300 U/l). The urine specific gravity was 1.038, thus the urine was adequately concentrated.
Management and outcome
The cat was treated with a modified version of the University of Wisconsin-Madison protocol for feline lymphoma, a chemotherapy protocol based on CHOP (vincristine, doxorubicin, cyclophosphamide and prednisolone), with discontinuation of therapy planned at 6 months (UWM-25). This included the following chemotherapeutic agents; vincristine (0.7 mg/m 2 IV; Pfizer Injectables/Hospira Australia), cyclophosphamide (200 mg/m 2 PO; Baxter Healthcare), doxorubicin (1 mg/kg IV; Accord Healthcare) and prednisolone (2 mg/kg PO q24h [tapering course]; Mavlab). Oral transmucosal buprenorphine hydrochloride (0.03 mg/kg) was used intermittently for analgesia. Four weeks following commencement of chemotherapy, progressive disease was noted within the cutaneous lesion ( Figure 5 ) and right axillary lymph node. Palliative surgery (amputation) and rescue chemotherapy were discussed. The owner elected to euthanase the cat 1 week later, 42 days postdiagnosis, and a necropsy was declined.
Discussion
To our knowledge, this is the first report of a possible association between the development of CNEL and a previous fracture site in a cat.
Feline primary cutaneous lymphoma is a rare malignancy seen predominately in older cats, representing 0.2-3% of all feline lymphomas. 1 This malignancy can present as epitheliotropic T-cell lymphoma, with preference for invasion of the epidermis and adexenal epithelium. 2 It can also present as the non-epitheliotropic form, which invades the dermis and subcutis. 1, 3 The underlying aetiology of cutaneous lymphoma is not well understood; however, chronic inflammation is thought to be a risk factor for its development.
Historically, it was thought that CNEL was not associated with presence of feline leukaemia virus (FeLV); however, recent studies have questioned this assumption. 3 A study by Weiss et al found that 80% of feline primary cutaneous lymphoma cases studied detected either FeLV antigen or the provirus. 4 Another report described a case of CNEL that tested negative for FeLV using serum ELISA; however, PCR detected a fragment of proviral FeLV. 5 Furthermore, a recent study examining the development of CNEL associated with previous injection sites demonstrated the presence of FeLV proteins gp70 and p23, in 10/17 cases examined. 1 Therefore, FeLV may play a role in the aetiology of cutaneous lymphoma, and these recent cases may represent an improvement in the techniques available for virus detection. 4 Some authors have questioned the significance of the presence of proviral DNA in the absence of FeLV antigens. 6, 7 There are doubts over the significance of latent FeLV infection in the aetiology of lymphoma development. [6] [7] [8] More research with larger populations is required to further elucidate this relationship.
There are numerous reports of the development of neoplasms at sites of foreign material in dogs, cats and humans. It has been clearly demonstrated that sarcomas can develop at sites of injections or retained surgical material in cats. [9] [10] [11] Interestingly, there have also been several published cases of fracture-associated sarcomas arising in dogs and humans. 12, 13 A recent retrospective study found 16 cases of dogs that had developed sarcomas associated with metallic implants. Osteosarcoma was by far the most common tumour seen, followed by single cases of histiocytic sarcoma, fibrosarcoma and spindle-cell sarcoma. 13 Feline cases of implant-associated malignancy have rarely been reported in the literature. One case report described osteosarcoma in a cat that developed at the site of a metal implant used to repair a fracture in the proximal femur 15 months earlier. 14 Cutaneous lymphoma is reported to have arisen at regions of injection-site sarcomas in cats, following chemotherapy or radiation treatment of the primary tumour. It is hypothesised that this may be due to the mutagenic effects of these treatments. 15 One study described 17 cases of feline primary cutaneous lymphoma that developed at injection sites, without any association with sarcomas. Eleven cases were considered large B-cell lymphoma, three cases were anaplastic large T-cell lymphoma, one case was classified as natural killer cell-like lymphoma and one case was considered peripheral T-cell lymphoma. 16 Time to tumour development post-injection ranged from 15 days to approximately 9 years. Cutaneous lymphomas at injection sites in this study shared some clinical and pathological features with feline injectionsite sarcomas and with lymphomas developing in the setting of subacute-to-chronic inflammation reported in human beings, with all cases lacking epitheliotropism. The authors proposed a possible mechanism involving chronic inflammation from an immunogenic stimulus, and reactivation of FeLV expression, enabling viral transformation of lymphocytes in certain cases. 1 To date, there have been no reports of cutaneous lymphoma at a previous fracture site in either canine or feline patients. There have been several cases of nonHodgkin B-cell lymphoma occurring at the site of a metallic implant in humans. 17, 18 Recently, there was also a report of an anaplastic large-cell T-cell lymphoma occurring in a human patient, associated with a metal implant. 18 A study in rats with orthopaedic implants showed a direct association between the development of sarcoma or lymphoma and the presence of this implant. The study also found intramedullary implants were associated with an increased incidence of neoplasia, indicating that location of the surgical device plays a key role in oncogenic transformation. 19 The authors of this report, and others, have hypothesised that metal implants may play a key role in tumour pathogenesis, and may influence metabolic, immunogenic and oncogenic processes via chronic antigenic stimulation and inflammation. 12, [19] [20] [21] Others hypothesise that trauma itself can play a role in malignant transformation. In some cases, sarcomas develop at the site of the previous fracture, rather than at the location of surgical implants. 22 It is likely, however, that multiple factors influence malignant transformation, including chronic inflammation, aberrant healing processes, genetic and epigenetic factors, and possibly a carcinogenic role of metal implants.
Protocols for treatment of cutaneous lymphoma in cats have not been standardised or widely reported. For local lesions, surgery or radiation can be considered following staging to rule out distant disease. 23 Furthermore, there has been a report of a complete remission to lomustine in a cat with non-epitheliotropic lymphoma; therefore, this treatment could be considered in cases of disseminated disease. 24 One study examined 23 cases of feline cutaneous lymphoma treated at a number of veterinary hospitals. Nine patients were treated with a CHOPbased protocol, either with or without L-asparaginase or lomustine. Response rates were variable, with some cats maintaining stable disease, and one cat achieving a complete remission. Radiotherapy was also trialled in combination with chemotherapy. The study maintained that other treatment protocols should be investigated; however, a multi modal approach would likely achieve the best control of the disease. 23 This case had several limitations in relation to the diagnostic work-up, absence of full staging once the diagnosis was confirmed, lack of FeLV testing and the inability to perform a necropsy. Many of these were related to financial restrictions, as is encountered in non-funded, retrospective cases. During the diagnostic work-up, antibiotics were administered multiple times before further diagnostics were performed, despite no evidence of overt infection (degenerate neutrophils only on cytology) and a lack of response to previous antibiotic therapy. There was also no attempt to confirm an infection using culture and sensitivity of the affected area. Finally, there was a significant delay in obtaining a histopathological diagnosis, as owing to cost constraints the sample was not submitted for 2 months after collection. It is not possible to determine if an earlier diagnosis may have affected outcome in this case. However, in retrospect, any lesions that occur particularly if associated with a site of previous trauma or surgery -should be carefully assessed, and, in the absence of overt infection or a conclusive cytological diagnosis, should be biopsied. It is unusual that cytology from the local site on two occasions did not reveal an increased population of lymphocytes, as noted on the biopsy, as lymphocytes generally exfoliate well and lymphoma is often diagnosed with cytology. It is possible the cytological samples were too superficial and not representative of the deeper, underlying disease process centred around the fracture site and implant. It is also possible the lymphoma developed after the cytological samples were collected, particularly the first sample, as this preceded the incisional biopsy by 12 months. This would seem less likely for the second cytological sample, which was collected only 7 weeks prior to biopsy.
The cytological findings from regional lymph node aspirates were consistent with at least stage II disease, with confirmed involvement of two peripheral nodes. It is possible this case presented as true stage II disease without further systemic involvement; however, it is not possible to differentiate loco-regional disease from systemic disease without full staging. There are numerous possible explanations for the presence of rare atypical lymphocytes in circulation. First, the atypical lymphocytes may have represented a spillover effect from the enlarged lymph nodes or cutaneous site, particularly as the lymphocyte count remained within normal range. Alternatively, it may have represented stage V involvement. It also remains possible these were atypical reactive lymphocytes. Finally, the presence of these cells may have occurred as a result of spillover from another location, such as the spleen. As splenic aspirates were not performed, this could not be ruled out.
Further staging, including bone marrow aspiration, thoracic and abdominal imaging and feline immunodeficiency virus/FeLV testing was recommended and was declined by the owner. These staging tests would have clarified the extent of disease and directed treatment options. If no distant disease beyond the dermal site and loco-regional lymph nodes was noted, amputation could have been considered, in combination with systemic chemotherapy. This may have improved outcome, although further studies are required to clarify the role of local treatments in this disease. If distant disease was noted on staging tests, then proceeding directly to chemotherapy would have been indicated. Without staging, and necropsy, it was assumed the lesion over the right forelimb was the primary site, with involvement of the loco-regional lymph nodes. It remains possible that the lymphoma developed in another organ (centralised phenomenon) and developed a tropism for the cutaneous site mediated by the inflammatory process. In future, staging and/or necropsy would be useful to assess the extent of involvement, further evaluating local and systemic disease presence. This may have clarified whether chronic inflammation associated with the fracture, or metal implant had an aetiological role in the development of the cancer, or rather supplied an ideal environment for the cancer to traffic to and thrive at.
Conclusions
To our knowledge, this is the first report of CNEL developing at the site of a previous fracture and metal implant in a cat. Owing to the low incidence of reported cases, more investigation is required to understand the association between the development of lymphoma and other malignancies, at sites of previous trauma, and in the presence of surgical implants. To improve outcome, prompt sampling of lesions associated with previous fracture or surgical sites should be performed in cases where overt infection is not detected.
